BioDelivery Sciences has received a $1.3m grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B to further study the formulation in the treatment of Cutaneous Leishmaniasis. Bioral Amphotericin B is an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology.
Reportedly, BDSI is developing a Bioral formulation of amphotericin B for the potential oral treatment of fungal infections such as Esophageal Candidiasis and parasitic diseases such as Leishmaniasis.
Earlier this year, BDSI announced the results of a phase 1 clinical study of the Bioral formulation of amphotericin B identifying doses that were well tolerated.
David Blum, vice president of medical affairs and clinical research for BioDelivery Sciences, said: “We are delighted to be given this opportunity to continue research on a treatment of such potential importance, especially in a competitive grant environment. If the clinical study program yields positive results, it could potentially result in a significant improvement in the treatment options for this disease.”